Antitumor activity of an interleukin-2 monoclonal antibody in a murine osteosarcoma transplantation model

Anticancer Research

Volumn 32, Issue 3, 2012, Pages 779-782

  Kohyama, Keishi ^a   Sugiura, Hideshi ^a   Kozawa, Eiji ^b   Wasa, Junji ^b   Yamada, Kenji ^a   Nishioka, Akiko ^c   Kamei, Yuzuru ^b   Taguchi, Osamu ^c  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

Interleukin 2 monoclonal antibody; LM8 cell line; Metastasis; Murine model; Osteosarcoma; Regulatory T cell

Indexed keywords

ANTINEOPLASTIC AGENT; INTERLEUKIN 2 MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY; S4B6; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DISTANT METASTASIS; DRUG EFFICACY; HUMAN; HUMAN CELL; LUNG METASTASIS; MALE; MOUSE; NONHUMAN; OSTEOSARCOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TUMOR VOLUME;

ANIMALS; ANTIBODIES, MONOCLONAL; DISEASE MODELS, ANIMAL; INTERLEUKIN-2; MALE; MICE; MICE, INBRED C3H; NEOPLASM TRANSPLANTATION; OSTEOSARCOMA;

EID: 84858787114     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Mirabello L, Troisi RJ and Savage SA: Osteosarcoma incidence and survival rates from 1973 to 2004: date from the surveillance, epidemiology, and end results program. Cancer 115: 1531-1543, 2009.
2. Ferrari S, Briccoli A, Mercuri M, Bertoni F, Picci P, Tienghi A, Del Prever AB, Fagioli F, Comandone A and Bacci G: Postrelapse survival in osteosarcoma of the extremities: prognostic factors for long-term survival. J Clin Oncol 21: 710-715, 2003. (Pubitemid 46621907)
3. Li X, Jung C, Liu YH, Bae KH, Zhang YP, Zhang HJ, Vanderputten D, Jeng MH, Gardner TA and Kao C: Antitumor efficiency of a transcriptional replication-competent adenovirus, Ad-OC-E1a, for osteosarcoma pulmonary metastasis. J Gene Med 8: 679-689, 2006.
4. Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T and Nakayama E: Tumor rejection by in vivo administration of antiCD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res 59: 3128-3133, 1999. (Pubitemid 29316012)
5. + T-cells: a common basis between tumor immunity and autoimmunity. J Immunol 163: 5211-5218, 1999.
6. Kozawa E, Sugiura H, Wasa J, Kohyama K, Yamada K, Nishioka A, Nishida Y, Ishiguro N and Taguchi O: Suppression of tumor metastasis in a murine osteosarcoma model with anti-CD25 monoclonal antibody treatment. Anticancer Res 30: 5019-5022, 2010.
7. Taguchi O and Takahashi T: Administration of anti-interleukin-2 receptor alpha antibody in vivo induces localized autoimmune disease. Eur J Immunol 26: 1608-1612, 1996. (Pubitemid 26230010)
8. Kamimura D, Sawa Y, Sato M, Agung E, Hirano T and Murakami M: IL-2 in vivo activities and antitumor efficacy enhanced by an anti-IL-2 mAb. J Immunol 177: 306-314, 2006. (Pubitemid 43939142)
9. + regulatory T-cell function: IL-2, IL-4, IL-7 and IL-15 preserve optimal suppressive potency in vitro. Int Immunol 19: 785-799, 2007.
10. Setoguchi R, Hori S, Takahashi T and Sakaguchi S: Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T-cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J Exp Med 201: 723-735, 2005. (Pubitemid 40395118)